These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 33771892)

  • 21. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.
    Yu Q; Zhang L; Ouyang L; Gong Y; Liang Z; Shen G; Weng X; Wu X
    Immunogenetics; 2013 Mar; 65(3):173-84. PubMed ID: 23233149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
    Knutson KL; Disis ML
    Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
    Li Q; Hu W; Liao B; Song C; Li L
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
    Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
    J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
    Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
    Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
    Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
    J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
    Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
    Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8
    Shi W; Qiu Q; Tong Z; Guo W; Zou F; Feng Z; Wang Y; Huang W; Qian H
    Eur J Med Chem; 2020 Mar; 189():112051. PubMed ID: 31968280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
    Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
    Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
    Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
    Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
    Willimsky G; Beier C; Immisch L; Papafotiou G; Scheuplein V; Goede A; Holzhütter HG; Blankenstein T; Kloetzel PM
    Elife; 2021 Apr; 10():. PubMed ID: 33875134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
    Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
    Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.
    Ohkuri T; Wakita D; Chamoto K; Togashi Y; Kitamura H; Nishimura T
    Br J Cancer; 2009 Apr; 100(7):1135-43. PubMed ID: 19277034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.